B7-H3 NIR Imaging for Osteosarcoma Surgery

Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen-section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved. Herein, based on the high expression of B7-H3 in OS, a targeted probe B7H3-IRDye800CW is synthesized by conjugating anti-B7H3 antibody and IRDye800CW.

Trial Details

NCT ID
NCT06778603
Phase
PHASE1 / PHASE2
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • a targeted probe B7H3-IRDye800CW
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. Patients with histologically confirmed osteosarcoma of the limbs.
  • 2\. the patients has not undergone tumor resection.
  • 3\. Age between 18 and 60 years old.
  • 4\. No prior systemic treatment for osteosarcoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →